Deepak Srivastava, MD, is President of Gladstone Institutes, a nonprofit biomedical research institute that uses visionary science and technology to overcome disease. He is also a senior investigator and director of the Roddenberry Stem Cell Center at Gladstone. In addition, he is a professor in the Departments of Pediatrics and Biochemistry and Biophysics, and the Wilma and Adeline Pirag Distinguished Professor in pediatric developmental cardiology at UC San Francisco (UCSF). Srivastava received his MD from the University of Texas, then trained in pediatrics at UCSF and in pediatric cardiology at the Children’s Hospital of Harvard Medical School. Before joining Gladstone in 2005, Srivastava was a professor of pediatrics and molecular biology at the University of Texas Southwestern Medical Center in Dallas. He became Gladstone’s president in 2018, and has since been steering the organization toward a new era of convergence between technology and biomedical research. In his lab, Srivastava investigates the genes responsible for normal heart formation and congenital heart disease, and harnesses this knowledge to engineer cells that can repair heart damage. Srivastava is a member of the American Society for Clinical Investigation, the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the National Academy of Medicine. He served as president of the International Society for Stem Cell Research in 2019–2020. In addition, Srivastava has co-founded two biotechnology companies, iPierian Inc. and Tenaya Therapeutics, where he continues to sit on the board of directors and on the scientific advisory board. Srivastava was recently recognized in the San Francisco Business Times’ Power 100 list for his leadership in business and research in the Bay Area.